Scarica l'app Stockscreener
3.77
10.66%
-0.45
Dopo l'orario di chiusura:
3.75
-0.02
-0.53%
Precedente Chiudi:
$4.22
Aprire:
$4.25
Volume 24 ore:
1.15M
Relative Volume:
1.89
Capitalizzazione di mercato:
$209.92M
Reddito:
-
Utile/perdita netta:
$-31.39M
Rapporto P/E:
-4.4881
EPS:
-0.84
Flusso di cassa netto:
$-18.45M
1 W Prestazione:
-3.33%
1M Prestazione:
+124.40%
6M Prestazione:
+163.64%
1 anno Prestazione:
+85.71%
Intervallo 1D:
$3.73
$4.25
Intervallo di 1 settimana:
$3.73
$4.5499
Portata 52W:
$0.7203
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
Nome
Quince Therapeutics Inc
Settore
Industria
Telefono
415-910-5717
Indirizzo
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Confronta QNCX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
3.77 | 234.98M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-05 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Iniziato | Oppenheimer | Outperform |
Quince Therapeutics Inc Borsa (QNCX) Ultime notizie
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Quince Therapeutics (NASDAQ:QNCX) Price Target Raised to $5.00 at D. Boral Capital - MarketBeat
Quince marks final patient visit in NEAT phase 3 study - marketscreener.com
Quince Marks Final Patient Visit in NEAT Phase 3 Study - TradingView — Track All Markets
Quince Therapeutics (QNCX) Concludes Phase 3 Trial for Key Drug - GuruFocus
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Yahoo Finance
Citizens reiterates Market Outperform rating on Quince Therapeutics stock By Investing.com - Investing.com Canada
Quince Therapeutics publishes early-stage data on eDSP drug delivery system - Investing.com Nigeria
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - BioSpace
Citizens reiterates Market Outperform rating on Quince Therapeutics stock - Investing.com India
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonar - pharmiweb.com
Quince Therapeutics (QNCX) Publishes Promising Early Clinical Study Results - GuruFocus
Check out these key findings about Quince Therapeutics Inc (QNCX) - setenews.com
Trading Action: Is Quince Therapeutics Inc stock a safe buy before earnings2025 Price Momentum & Accurate Trade Setup Notifications - moha.gov.vn
Quince Therapeutics, Inc. (QNCX) -11.5% in After-hours: No Clear Catalyst Driving Decline - Stocks Telegraph
Quince Therapeutics, Inc. (QNCX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why Quince Therapeutics Inc. stock is trending among retail traders2025 Performance Recap & Real-Time Buy Signal Alerts - Newser
Why Quince Therapeutics Inc. stock remains resilientWeekly Investment Recap & Weekly Top Stock Performers List - Newser
Quince Therapeutics (QNCX) Stock Analysis Report | Financials & Insights - Benzinga
Prepare Yourself for Liftoff: Quince Therapeutics Inc (QNCX) - Setenews
Quince Therapeutics Stock Surges 105%, With A 8-Day Winning Spree - Trefis
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Consensus Target Price from Analysts - Defense World
Quince Therapeutics, Inc. (QNCX) 18.8% in Intraday Trading: Surge Amid Upcoming Investor Events - Stocks Telegraph
Quince Therapeutics Stock Rockets 59% With 7-Day Winning Streak - Trefis
Quince Therapeutics: Could NEAT Phase 3 Data Deliver The First Therapy For Ataxia-Telangiectasia? - RTTNews
Adversity is less terrifying than hope: Quince Therapeutics Inc (QNCX) - Setenews
EBITDA per share of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics to Participate at Investor Events in December 2025 - Markets Financial Content
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Quince Therapeutics Inc. stock a dividend growth opportunity2025 Historical Comparison & Growth Oriented Trade Recommendations - newser.com
A new trading data show Quince Therapeutics Inc (QNCX) is showing positive returns. - setenews.com
Can Quince Therapeutics Inc. stock weather global recessionWeekly Stock Recap & Detailed Earnings Play Alerts - newser.com
Sentiment analysis tools applied to Quince Therapeutics Inc.Quarterly Portfolio Report & Weekly High Conviction Ideas - newser.com
How analysts rate Quince Therapeutics Inc. stock todayM&A Rumor & Low Risk Entry Point Tips - newser.com
Statistical indicators supporting Quince Therapeutics Inc.’s strengthGDP Growth & Technical Entry and Exit Alerts - newser.com
Can Quince Therapeutics Inc. stock double in next 5 yearsMarket Trend Review & Weekly Hot Stock Watchlists - newser.com
Combining machine learning predictions for Quince Therapeutics Inc.Global Markets & Daily Chart Pattern Signal Reports - newser.com
Is Quince Therapeutics Inc. stock a good choice for value investorsMarket Risk Summary & Risk Managed Investment Strategies - newser.com
How interest rate cuts could boost Quince Therapeutics Inc. stockShort Setup & Daily Oversold Stock Bounce Ideas - newser.com
What indicators show strength in Quince Therapeutics Inc.July 2025 Levels & Weekly High Return Opportunities - newser.com
Is Quince Therapeutics Inc. stock oversold or undervaluedJuly 2025 Price Swings & Reliable Breakout Forecasts - newser.com
Quince Therapeutics Inc Azioni (QNCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):